The U.S. Food and Drug Administration approved Immunocore’s Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
At least 1 in 5 Americans have been infected with COVID-19. In other news, the U.S. Food and Drug Administration approved Gilead Sciences’ supplemental New Drug Application for Veklury (remdesivir) for adults and adolescents with COVID-19 who are not hospitalized but are at high risk of progression to severe COVID-19, hospitalization or death.
The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.
The U.S. Food and Drug Administration approved drugs from AbbVie Inc. and Pfizer Inc. for treating the skin disease eczema, the companies said on Jan. 14.
The U.S. health regulator on January 13 approved Zoetis Inc,’s once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.
The U.S. Food and Drug Administration approved Swiss drugmaker Idorsia’s treatment for insomnia in adult patients.
The U.S. Food and Drug Administration approved Xeris Biopharma Holdings Inc.’s Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.
BioSpace reviews the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) as the first drug approved for Alzheimer’s disease in almost 20 years.
The U.S. Food and Drug Administration approved the first treatment that addresses IL-13 cytokine in adults diagnosed with moderate to severe atopic dermatitis.
The U.S. Food and Drug Administration approved Novartis’
Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis in patients 4 years and older, and active psoriatic arthritis in patients 2 years and older.
